Abstract: The compound referred to herein as IB-962 12, having structure (I) can be obtained by cultivating the strain of Micromonospora sp. ES25-008, available under the accession number CECT-3333, and can be hydrolyzed to give IB-96212B having structure (II). The sugar substituent which is L-rhodinose, can its elf be derivatized or the sugar can be replaced, in either case, giving further derivatives of IB-96212 having a group other than L-rhodinose at the position of the sugar.

Abstract: The invention relates to a process for preparation of the vancomycin antibiotic in a microbiological way by aerobic fermentation, by using a strain belonging to the Micropolyspora species in a culture-medium containing assimilable carbon and nitrogen sources as well as mineral salts. According to the invention as microorganisms the aminoglycoside-resistant NCAIM 001092 and NCAIM 001093 mutants of the strain belonging to the Micropolyspora orientalis species are used. Nitrates are suitable mineral salts in the fermentation. Soy flour, glycerol, calcium gluconate, starch are useful carbon sources. The fermentation is carried out preferably at a temperature of 29.degree.-30.degree. C. The vancomycin antibiotic produced in the fermentation is separated by using reverse osmosis and ultrafiltration following ion-exchange chromatography.

Abstract: This disclosure describes novel antibacterial agents designated LL-E10985.alpha., LL-E19085.beta., LL-E19085.gamma., LL-E19085.zeta. and LL-E19085.eta., having the structure: ##STR1## their production by aerobic fermentation of a new subspecies of Micromonospora citrea NRRL 18351 and mutants thereof, and the isolation and purification thereof.

Abstract: Antibacterial and antitumor agents designated LL-E33288 complex and their production by new strains of Micromonospora echinospora spp. calichensis NRRL-15839, NRRL-15975 and NRRL-18149, are disclosed.

Abstract: This disclosure describes novel antibacterial agents designated LL-E10985.alpha., LL-E19085.beta., LL-E19085.gamma., LL-E19085.gamma. and LL-E19085.zeta., having the structure: ##STR1## their production by aerobic fermentation of a new subspecies of Micromonospora citrea NRRL 18351 and mutants thereof, and the isolation and purification thereof.

Abstract: Dihydro derivatives of LL-E33288, BBM-1075 FR-900405, FR-900406, PD 114759, PD 115028, CL-1577A, CL-1577B, CL-1577D, CL-1577E and CL-1724 antibiotics/antitumor agents are disclosed and described, including the degradation product of LL-E33288 antibiotics/antitumor agents dihydro-LL-E33288-pseudoaglycone.

Abstract: A new species of Micromonospora, in particular Micromonospora spartanea ATCC 53803, is described. The species produces new antifungal compounds spartanamicins A and B. Methods for the production, isolation and characterization of the compounds are described. The new compounds contain spartanose, which is a new hexose sugar, as well as another hexose and an amino sugar.

Abstract: Antibacterial and antitumor agents designated LL-E33288 complex and their production by new strains of Micromonospora echinospora ssp. calichensis NNRL-15839, NRRL-15975 and NRRL-18149, are disclosed.

Abstract: The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-1 (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.

Abstract: A biologically pure culture of Micromonospora purpureochromogenes ssp. Wuxiensis and its use in an aerobic fermentation process to produce the antibacterial and antiparasitic agent LL-D42067.alpha..

Abstract: Novel microorganisms belonging to the genus Micromonospora capable of producing antibiotics YS-02930 K-D, -E or -H represented by formula: ##STR1## wherein R represents a hydrogen atom or a formyl group and a dotted line represents a double bond or a bond shown by: ##STR2## are disclosed. The antibiotics are produced by culturing bacteria belonging to the genus Micromonospora capable of producing at least one antibiotic selected from YS-02930 K-D, -E and -H and, harvesting antibiotic YS-02930 K-D, -E or -H.

Abstract: A new variety of Micromonospora carbonacea, namely Micromonospora carbonacea var africana NRRL 15099, ATCC 39149.

Abstract: Neuraminidase is produced by culturing a neuraminidase producing microorganism belonging to the genus Micromonospora. The neuraminidase is useful for the quantitative determination of a sialic acid-containing substance in a sample.

Abstract: New antibiotic substances arbitrarily designated M 9026 complex, antibiotic M 9026 factor 1, antibiotic M 9026 factor 2, and antibiotic M 9026 factor 3, produced by fermentation of a strain of the Micromonospora genus. The antibiotics of the invention are antimicrobial and antitumor agents.

Abstract: A method for producing S-adenosyl-L-homocysteine hydrolase, which comprises cultivating a microorganism having the ability to produce S-adenosyl-L-homocysteine hydrolase within its cells in a nutrient medium to accumulate said hydrolase in the cells, said microorganism being a bacterium belonging to the genera Alcaligenes, Pseudomonas, Acinetobacter, Arthrobacter, Enterobacter, Rhodopseudomonas, Agrobacterium, Micrococcus, Corynebacterium, Brevibacterium, Chromobacterium, Xanthomonas, Flavobacterium, Cellulomonas, Azotobacter and Protaminobacter, or an actinomycete belonging to the genera Streptomyces, Mycobacterium, Nocardia, Streptoverticillium, Micromonospora, Micropolyspora, Streptosporangium and Microellobosporia; and then recovering S-adenosyl-L-homocysteine hydrolase from the cells.

Abstract: A method of increasing the yield of a desired product, such as an antibiotic, by an organism which normally must first become inducibly resistant to that product before it can produce the product in maximum yields comprises producing constitutively resistant cells of the organism by supplementing a culture of the organism with an agent in which only cells able to specifically modify the 23S ribosomal RNA constitutively, rather than inducibly, survive thereby producing an organism in which the resistance to the product is expressed without the need for activation by the induction process; followed by purification and utilization of that organism for increased product production.

Abstract: Micromonospora danubiensis, a new species, having the capability of producing sisomicin.

Abstract: Sisomicin is produced by culturing Micromonospora danubienis.

Abstract: The Antiboitic AR-5 complex is elaborated by a novel species of the Micromonospora; namely, Micromonospora polytrota. The microorganism also elaborates a number of minor components including the gentamicin complex and a complex of anthroquinone antibiotics.

Abstract: A process of producing sisomycin by cultivating a new species of Micromonospora.

Abstract: A culture of Micromonospora rosea capable of producing the antibiotic sisomicin.

Abstract: New antibacterial compounds, XK-62-3 and XK-62-4, are produced by fermentation of microorganisms belonging to the genus Micromonospora. The compounds are accumulated in the culture liquor and are isolated therefrom.

Abstract: The invention provides a process for the preparation of antibiotic-producer Micromonospora strains having modified genetic material, wherein a protoplast suspension is prepared with lysozyme, under osmotically buffered conditions ensured by sucose, from each culture of the two genetically marked mutants of the antibiotic-producer Micromonospora strain following cultivation in a glycine medium, both suspensions obtained are combined in the presence of polyethylene glycol, and incubated at room temperature, the resulting fused protoplasts are suspended in soft agar, then plated on an agar plate containing sucrose, prolin and inorganic salts, incubated for 20 to 30 days, and finally all mutants are selected from the regenerated colonies which are sure to have genetic material different from that of the parent strains.The process can be advantageously applied to improve productivity of antibiotic-producer strains having industrial importance.

Abstract: A novel microorganism species belonging to the genus Micromonospora, i.e. Micromonospora sp. A 11725 is found to be capable of producing novel macrolide antibiotics A 11725 I, A 11725 II and A 11725 III. Novel antibiotics A 11725 Ia and A 11725 IIa are also found to be derived by chemical modification of the antibiotics A 11725 I and A 11725 II, respectively. All of these antibiotics or salts thereof exhibit excellent antibacterial and anti-mycoplasmal activities against various microorganisms such as Staphylococcus or Mycoplasma, and therefore useful for various purposes including medicaments.

Abstract: Aminoglycoside antibiotics biochemically transformed from Kanamycin A or Kanamycin B, which are represented by the formula ##STR1## wherein R.sub.1 represents a hydrogen atom or a methyl group and R.sub.2 represents an amino group or a hydroxyl group.

Abstract: A process for the production of gentamicins or more specifically a mixture of gentamicins C.sub.1, C.sub.2 and C.sub.1 a by the aerobic fermentation of a new species Micromonospora scalabitana closely related to Micromonospora narashinoensis in suitable medium containing assimilable sources of carbon and nitrogen, calcium carbonate and several trace elements.

Abstract: New antibiotic compounds, Fortimicin factors KG.sub.1, KG.sub.2 and KG.sub.3 are produced by fermentation of microorganisms belonging to the genus Micromonospora. The antibiotic compounds are accumulated in the culture liquor and are isolated therefrom.

Abstract: Rosaramicin, (also known as rosaramicin) a new broad spectrum antibiotic is described together with methods for its production via the cultivation under controlled conditions of Micromonospora rosaria, a new species of Micromonospora, and to methods for purifying and using the same. Its 2'-monoesters and its 3,2'-diesters and their acid addition salts also possess antibiotic activity.

Abstract: The microorganisms Micromonospora inyoensis 1550F-1G and M. purpurea strain 1124 each microbiologically convert tobramycin, kanamycin A, kanamycin B and dibekacin to their respective 3"-N-methyl and 3"-N-methyl-4"-C-methyl derivatives. The derivatives exhibit significant activity against representative gram positive and gram negative bacteria and may also be converted to other derivatives which have significant antibacterial activity.

Abstract: A substance which inhibits the enzyme .beta.-lactamase, produced by a wide range of microorganisms, is obtained when species of the microorganism Micromonospora are cultivated under aerobic fermentation conditions and this inhibitor can be isolated from the fermentation medium by extraction. This substance, denominated EM4615, is useful to enhance the effectiveness of .beta.-lactam antibiotics such as penicillins and cephalosporins.

Abstract: A new aminoglycoside antibiotic, Fortimicin E, is produced by fermentation of Micromonospora olivoasterospora ATCC 21819, 31009 and 31010 and isolated from the fermentation broth.

Abstract: A novel antibacterial compound, XK-99, is produced by fermentation of an organism belonging to the genus Micromonospora. The compound is isolated from the microbial cells and culture liquor.